Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03463
[1], [2]
Histone modification H3K27ac HDAC1 ALKBH5 Direct Inhibition m6A modification TP53 TP53 ALKBH5 Demethylation : m6A sites
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
m6A Target Cellular tumor antigen p53 (TP53/p53)
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 1 (HDAC1) ERASER View Details
Regulated Target Histone H3 lysine 27 acetylation (H3K27ac) View Details
Downstream Gene ALKBH5 View Details
Crosstalk Relationship Histone modification  →  m6A Inhibition
Crosstalk Mechanism histone modification directly impacts m6A modification through modulating the level of m6A regulator
Crosstalk Summary HDACi reduces ferroptosis suppressor protein (FSP1) by promoting its mRNA degradation. Specifically, it is confirmed that HDACi specifically targets HDAC1 and promotes the Histone H3 lysine 27 acetylation (H3K27ac) modification of fat mass- and obesity-associated gene (FTO) and AlkB Homolog 5, RNA Demethylase (ALKBH5), which results in significant activation of FTO and ALKBH5. The activation of FTO and ALKBH5 reduces N6-methyladenosine (m6A) modification on FSP1 mRNA, leading to its degradation. Crucially, lactylation of HDAC1K412is essential for ferroptosis regulation. Both Vorinostat (SAHA) and Trichostatin A (TSA) notably diminish HDAC1K412lactylation in comparison to other HDAC1 inhibitors, exhibiting a consistent trend of increasing susceptibility to ferroptosis. The interplay between CARMN and ALKBH5 promoted tumourigenesis in colorectal cancer patients via the Cellular tumor antigen p53 (TP53/p53)/ALKBH5/CARMN/miR-5683 pathway. These findings illuminate the role of m6A methylation in colorectal cancer patients with p53R273H mutation.
Responsed Disease Colorectal cancer ICD-11: 2B91
In-vitro Model
HIEC-6 Normal Homo sapiens CVCL_6C21
FHC Normal Homo sapiens CVCL_3688
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
HT29 Colon cancer Mus musculus CVCL_A8EZ
In-vivo Model Colorectal cancer cells were seeded in culture plates for 24 h prior to cotransfection with GFP-CARMN, and a vector using Lipofectamine 2000. After 48 h, RNA immunoprecipitation was performed using/Colorectal cancer cells were plated in 24-well plates and incubated for 24 h before cotransfection with the luciferase reporter vector, and the Renilla vector. antibodies against FTO, METTL3 and ALKBH5 from the EZ-Magna RIP Kit (Millipore).
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Cellular tumor antigen p53 (TP53/p53) 27 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
MOA Modulator
External Link
 Compound Name QPI-1002 Phase 3 [4]
MOA Modulator
External Link
 Compound Name Thymoquinone Phase 2/3 [5]
Synonyms
490-91-5; Thymoquinon; p-Cymene-2,5-dione; 2-Isopropyl-5-methyl-1,4-benzoquinone; 2,5-CYCLOHEXADIENE-1,4-DIONE, 2-METHYL-5-(1-METHYLETHYL)-; 2-Isopropyl-5-methyl-p-benzoquinone; 2-Isopropyl-5-methylbenzoquinone; Polythymoquinone; 5-Isopropyl-2-methyl-1,4-benzoquinone; 2-Isopropyl-5-methylbenzo-1,4-quinone; p-Mentha-3,6-diene-2,5-dione; NSC 2228; 2-Isopropyl-5-methylcyclohexa-2,5-diene-1,4-dione; 2-Methyl-5-isopropyl-p-benzoquinone; 2-methyl-5-propan-2-ylcyclohexa-2,5-diene-1,4-dione; NSC2228; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione; UNII-O60IE26NUF; 2-Methyl-5-isopropyl-1,4-benzoquinone; O60IE26NUF; 2,5-Cyclohexadiene-1,4-dione, 5-isopropyl-2-methyl-; NSC-2228; 5-Isopropyl-2-methyl-p-benzoquinone; MFCD00001602; 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione; p-Mentha-3,6-diene-2,5-dione (8CI); 5-Isopropyl-2-methyl-2,5-Cyclohexadiene-1,4-dione; CCRIS 7152; EINECS 207-721-1; 2-methyl-5-(methylethyl)cyclohexa-2,5-diene-1,4-dione; BRN 1939047; thymolquinone; Thymoil; AI3-17758; 4hco; p-Mentha-3,5-dione; Spectrum_001237; SpecPlus_000457; Thymoquinone, >=98%; Spectrum2_000700; Spectrum3_001345; Spectrum4_001895; Spectrum5_000550; BSPBio_003129; KBioGR_002455; KBioSS_001717; DivK1c_006553; SCHEMBL542535; SPBio_000859; CHEMBL1672002; DTXSID9060079; KBio1_001497; KBio2_001717; KBio2_004285; KBio2_006853; KBio3_002349; Thymoquinone, analytical standard; CHEBI:113532; 2-Methyl-5-iso-propylbenzoquinone; BDBM166686; ZINC164367; BCP16946; HY-D0803; WLN: L6V DVJ B1 EY1&1; 2,4-dione, 5-isopropyl-2-methyl-; ANW-41600; CCG-40027; s4761; SBB008296; AKOS003368628; MCULE-9899033250; NCGC00178250-01; NCGC00178250-05; 73940-92-8; AK101679; AS-11327; 2-Isopropyl-5-methylbenzo-1,4-quinone #; 2,4-dione, 2-methyl-5-(1-methylethyl)-; CS-0012226; FT-0612708; ST45023960; K-9199; SR-05000002192; Q7799650; SR-05000002192-2; W-202869; BRD-K97566842-001-03-5; 2-methyl-5-(propan-2-yl)cyclohexa-2,5-diene-1,4-dione (F8); 2-Methyl-5-(1-methylethyl)-2,5-cyclohexadiene-1,4-dione, 9CI
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name SGT-53 Phase 2 [6]
Synonyms
P53 gene stimulator (solid tumor), Synergene Therapeutics
    Click to Show/Hide
MOA Stimulator
External Link
 Compound Name APR-246 Phase 2 [7]
Synonyms
Eprenetapopt
    Click to Show/Hide
MOA Stimulator
External Link
 Compound Name Ad-p53 Phase 2 [8]
Synonyms
P53 gene therapy, Transgene/Schering-Plough; Ad-p53, Transgene/Schering-Plough
    Click to Show/Hide
MOA Modulator
External Link
 Compound Name Kevetrin Phase 2 [9]
MOA Stimulator
External Link
 Compound Name INGN-225 Phase 2 [10]
Synonyms
Cancer vaccine (p53), Introgen
    Click to Show/Hide
External Link
 Compound Name ALT-801 Phase 2 [11]
Synonyms
ALT-801 (donor lymphocyte infusion, cancer); ALT-801 (donor lymphocyte infusion, cancer), Altor; STAR IL-2 conjugate (donor lymphocyte infusion, cancer), Altor; STAR-Ck (donor lymphocyte infusion, cancer), Altor; Soluble T-cell Antigen Receptor IL-2 conjugate (donor lymphocyte infusion, cancer), Altor
    Click to Show/Hide
MOA Immunomodulator (Immunostimulant)
External Link
 Compound Name APG-115 Phase 2 [9]
Synonyms
15Qau0SI9J; UNII-15QAU0SI9J; 1818393-16-6; APG 115 [WHO-DD]; SCHEMBL17189805; Bicyclo(2.2.2)octane-1-carboxylic acid, 4-((((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-1'',2''-dihydro-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-(3H)indol)-5'-yl)carbonyl)amino)-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name ISA-P53-01 Phase 1/2 [12]
Synonyms
P53-SLP; P53 vaccine (colorectal/ovarian cancer), ISA Pharmaceuticals; P53 vaccine (Montanide ISA-51 adjuvanted, colorectal/ovarian cancer), ISA Pharmaceuticals
    Click to Show/Hide
External Link
 Compound Name SAR-405838 Phase 1 [13]
Synonyms
AT-219; MI-147; MI-219; MI-319; MI-43; MI-5; MI-63; MI-772; MI-773; MI-519-64; P53-HDM2 protein interaction inhibitors (cancer); P53-HDM2 protein interaction inhibitors (cancer), Ascenta/Sanofi; P53-HDM2 protein interaction inhibitors (cancer), Ascenta/sanofi-aventis
    Click to Show/Hide
MOA Modulator
External Link
 Compound Name Dendritic cell vaccine Phase 1 [14]
Synonyms
Dendritic cell vaccine (injectable, head and neck cancer); Dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute; Mutant p53 peptide pulsed dendritic cell vaccine (injectable, head and neck cancer), National Cancer Institute
    Click to Show/Hide
External Link
 Compound Name ONYX-015 Phase 1 [15]
Synonyms
Dl1520; E1B-deleted adenovirus (cancer), ONYX
    Click to Show/Hide
MOA Modulator
External Link
 Compound Name COTI-2 Phase 1 [9]
Synonyms
UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
    Click to Show/Hide
MOA Modulator
External Link
 Compound Name CGM097 Phase 1 [4]
MOA Modulator
External Link
 Compound Name HDM201 Phase 1 [16]
MOA Inhibitor
External Link
 Compound Name INGN-234 Discontinued in Phase 2 [17]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
MOA Suppressor
External Link
 Compound Name Pifithrin-alpha Terminated [18]
Synonyms
P53 inhibitor, Univ of Illinois; PFT-alpha; PFT-beta; Pifithrin compounds, Quark; Pifithrin-beta
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name TAR-1 Terminated [19]
Synonyms
P53 protein modulator (single-chain antibody fragment, cancer), Ramot/Champions
    Click to Show/Hide
External Link
 Compound Name 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine Investigative [20]
Synonyms
PhiKan 083; [(9-ethyl-9H-carbazol-3-yl)methyl](methyl)amine; EN300-43214; 880813-36-5; AC1NGDXR; PhiKan-083; BAS 13152361; PhiKan-083 Hydrochloride; CHEMBL1235116; SCHEMBL20181195; AC1Q3123; ZINC3888893; STK511393; IMED102848735; AKOS000284549; MCULE-1841863738; DB08363; NCGC00379107-01; NCGC00379107-02; ST072505; [(9-ethylcarbazol-3-yl)methyl]methylamine; HY-108637; CS-0029368; [(9-ethylcarbazol-3-yl)methyl](methyl)amine; 1-(9-ethylcarbazol-3-yl)-N-methylmethanamine
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name NUTLIN-3 Investigative [21]
Synonyms
548472-68-0; 890090-75-2; nutlin-3A; nutlin 3; (+/-)-Nutlin3; CHEMBL211045; Nutlin 3(Random Configuration); MDM2 Antagonist, Nutlin-3, Racemic; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name NU-8231 Investigative [22]
Synonyms
SCHEMBL2454464; CHEMBL360944
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name OPI-1002 Phase 2 [23]
External Link
 Compound Name Cenersen Phase 2 [23]
External Link
 Compound Name AHL Investigative [23]
Synonyms
AHLi-11; SiRNA therapeutics (hearing loss), Quark; P53 gene-silencing siRNA (hearing loss), Quark
    Click to Show/Hide
External Link
 Compound Name PC14586 Phase 1/2 [23]
External Link
Histone deacetylase 1 (HDAC1) 250 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Panobinostat Approved [24]
Synonyms
Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.54 nM
External Link
 Compound Name Vorinostat Approved [24]
Synonyms
NHNPODA; SAHA; SHH; Zolinza; Merck brand of Vorinostat; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; SAHA cpd; Suberanilohydroxamic acid; Suberoylanilide hydroxamic acid; Vorinostat MSD; Vorinostat [USAN]; M344; MK0683; SKI390; WIN64652; MK-0683; SAHA, Suberoylanilide hydroxamic acid; SW-064652; Zolinza (TN); Vorinostat (JAN/USAN); N1-hydroxy-N8-phenyloctanediamide; Zolinza, MK-0683, SAHA; N'-hydroxy-N-phenyloctanediamide; N-Hydroxy-N'-phenyl octanediamide; N-Hyrdroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyloctanediamide; N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; Vorinostat (HDAC inhibitor)
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1.3 nM
External Link
 Compound Name Romidepsin Approved [25]
Synonyms
Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.0015 nM
External Link
 Compound Name HBI-8000 Phase 1/2 [4]
Synonyms
CS055; SCHEMBL5500152; GTPL8305; AKOS026750315; N-(2-amino-5-fluorophenyl)-4-{[3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide
    Click to Show/Hide
MOA Modulator
Activity IC50 = 167 nM
External Link
 Compound Name NVP-LAQ824 Phase 3 [26]
Synonyms
Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 0.55 nM
External Link
 Compound Name SNDX-275 Phase 3 [27]
Synonyms
Entinostat; Histone Deacetylase Inhibitor I; IN1470; MS 275; SNDX 275; MS 27-275; Ms-275; Entinostat (USAN/INN); MS-27-275; Pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate; Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate; Pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Pyridin-3-ylmethyl{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate; Carbamic acid, [[4-[[(2-aminophenyl)amino]carbonyl]phenyl] methyl]-, 3-pyridinylmethyl ester; Carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester; Entinostat, SNDX-275, MS-27-275, MS-275; N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide; N-(2-aminophenyl)-4-(N-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide; Carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester; 3-Pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 22 nM
External Link
 Compound Name ITF2357 Phase 3 [28]
Synonyms
Givinostat; Carbamic acid, N-(4-((hydroxyamino)carbonyl)phenyl)-, (6-((diethylamino)methyl)-2-naphthalenyl)methyl ester, hydrochloride (1:1)
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 2 nM
External Link
 Compound Name Resminostat Phase 2 [29]
Synonyms
864814-88-0; 4SC-201; RAS2410; Resminostat (RAS2410); UNII-1578EUB98L; (E)-3-(1-((4-((dimethylamino)methyl)phenyl)sulfonyl)-1H-pyrrol-3-yl)-N-hydroxyacrylamide; BYK408740; 1578EUB98L; Resminostat [INN]; 4SC 201; Resminostat 4SC-201; Resminostat (4SC-201); SCHEMBL295541; SCHEMBL295540; GTPL7502; EX-A542; DTXSID50235587; MolPort-027-720-936; AOB87187; BCP02538; 4SC201; ZINC13983495; s2693; AKOS030526945; SB16667; DB12392; CS-1521; API0013984; BC261895
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Sodium butyrate Phase 2 [30]
Synonyms
Butyrate sodium; Sodium butanoate; Sodium propanecarboxylate; OR8783; Butanoic acid, sodium salt; Butyric Acid, Na; Sodium butyrate (USP); Sodium n-butyrate; TPA/BA; Tetradecanoyl phorbol acetate/ sodium butyrate; Butanoic acid, sodium salt (1:1); Tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA)
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name SB-623 Phase 2 [31]
Synonyms
(E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 52 nM
External Link
 Compound Name MGCD-0103 Phase 2 [24]
Synonyms
Mocetinostat; MG 0103; MG 4230; MG 4915; MG 5026; MG0103; MG4230; MG4915; MG5206; MGCD 0103; MGCD0103; MG-0103; MG-4230; MG-4915; MG-5026; Mocetinostat, MGCD0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide; N-(2-Aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 9 nM
External Link
 Compound Name Phenylbutyrate Phase 2 [32]
Synonyms
Benzenebutyric acid; Phenyl butanoate; Phenyl butyrate; HDInhib_000004; Butanoic acid, phenyl ester; Butyric acid, phenyl ester; FR-2080; Gamma-Phenylbutyric acid; Omega-Phenylbutanoic acid; GAMMA-PHENYL-BUTYRIC ACID; Butyric acid, 4-phenyl-(8CI); 1-Phenylbutyric acid; 4-PHENYL-BUTANOIC ACID; 4-PHENYLBUTYRIC ACID; 4-Phenylbutanoic acid; 4-phenylbutans; 4-phenylbutyrate
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 64000 nM
External Link
 Compound Name CHR-3996 Phase 1/2 [33]
Synonyms
CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
 Compound Name SB-639 Phase 1 [31]
Synonyms
CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 11 nM
External Link
 Compound Name RG-2833 Phase 1 [4]
Synonyms
RG-FA; HDAC-1 inhibtors (Friedreich ataxia), RepliGen
    Click to Show/Hide
MOA Modulator
Activity Ki = 32 nM
External Link
 Compound Name OBP-801 Phase 1 [34]
MOA Inhibitor
Activity IC50 = 3.3 nM
External Link
 Compound Name PMID29671355-Compound-42 Patented [35]
MOA Inhibitor
Activity IC50 = 10 to 100 nM
External Link
 Compound Name PMID28092474-Compound-33d Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32u Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33a Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32a Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32j Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32z Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32g Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-34c Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32x Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33b Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32b Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32o Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33g Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33j Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33p Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33m Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32v Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID29671355-Compound-24 Patented [35]
MOA Inhibitor
Activity IC50 = 382 nM
External Link
 Compound Name PMID28092474-Compound-34b Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33e Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32t Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32c Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33i Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32r Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32h Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID29671355-Compound-65a Patented [35]
MOA Inhibitor
Activity IC50 = 13800 nM
External Link
 Compound Name PMID28092474-Compound-32y Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33h Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID29671355-Compound-38a Patented [35]
MOA Inhibitor
Activity IC50 > 1000 nM
External Link
 Compound Name PMID28092474-Compound-33f Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name Diaryl amine derivative 3 Patented [36]
Synonyms
PMID28092474-Compound-11
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 460 nM
External Link
 Compound Name PMID28092474-Compound-33c Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID29671355-Compound-39 Patented [35]
MOA Inhibitor
Activity IC50 = 3840 nM
External Link
 Compound Name PMID29671355-Compound-19 Patented [35]
MOA Inhibitor
Activity IC50 = 500 to 1000 nM
External Link
 Compound Name PMID28092474-Compound-32e Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32m Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32p Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32d Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32n Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-33k Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32k Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-34a Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name Isosteric imidazolyl pyrimidine derivative 1 Patented [37]
Synonyms
PMID26161698-Compound-37
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 656 nM
External Link
 Compound Name PMID29671355-Compound-22 Patented [35]
MOA Inhibitor
Activity IC50 = 2100 nM
External Link
 Compound Name PMID29671355-Compound-26 Patented [35]
MOA Inhibitor
Activity IC50 = 8750 nM
External Link
 Compound Name PMID28092474-Compound-33o Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32f Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name Diaryl amine derivative 2 Patented [36]
Synonyms
PMID28092474-Compound-10
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 240 nM
External Link
 Compound Name PMID28092474-Compound-33l Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32i Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32q Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID29671355-Compound-18 Patented [35]
MOA Inhibitor
Activity IC50 > 10000 nM
External Link
 Compound Name PMID29671355-Compound-57 Patented [35]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
 Compound Name PMID29671355-Compound-27 Patented [35]
MOA Inhibitor
Activity IC50 = 187 nM
External Link
 Compound Name PMID28092474-Compound-32l Patented [36]
MOA Inhibitor
Activity IC50 >= 1000 nM; IC50 <= 10000 nM
External Link
 Compound Name PMID28092474-Compound-32s Patented [36]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID29671355-Compound-38b Patented [35]
MOA Inhibitor
Activity IC50 = 226 nM
External Link
 Compound Name PMID29671355-Compound-28 Patented [35]
MOA Inhibitor
Activity IC50 = 28 nM
External Link
 Compound Name PMID29671355-Compound-59 Patented [35]
MOA Inhibitor
Activity IC50 = 3 nM
External Link
 Compound Name PMID29671355-Compound-55 Patented [35]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
 Compound Name PMID29671355-Compound-73 Patented [35]
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
 Compound Name PMID29671355-Compound-13 Patented [35]
MOA Inhibitor
Activity IC50 >= 10000 nM
External Link
 Compound Name PMID29671355-Compound-11 Patented [35]
MOA Inhibitor
Activity IC50 = 21 nM
External Link
 Compound Name PMID29671355-Compound-9 Patented [35]
MOA Inhibitor
Activity IC50 = 94 nM
External Link
 Compound Name PMID29671355-Compound-8 Patented [35]
MOA Inhibitor
Activity IC50 = 16900 nM
External Link
 Compound Name PMID29671355-Compound-61 Patented [35]
MOA Inhibitor
Activity IC50 = 2.6 nM
External Link
 Compound Name PMID29671355-Compound-23 Patented [35]
MOA Inhibitor
Activity IC50 = 3620 nM
External Link
 Compound Name PMID29671355-Compound-44 Patented [35]
MOA Inhibitor
Activity IC50 < 150 nM
External Link
 Compound Name PMID29671355-Compound-56 Patented [35]
MOA Inhibitor
Activity IC50 = 8700 nM
External Link
 Compound Name PMID29671355-Compound-67 Patented [35]
MOA Inhibitor
Activity IC50 = 2900 nM
External Link
 Compound Name PMID29671355-Compound-31 Patented [35]
MOA Inhibitor
Activity IC50 = 0.3 nM
External Link
 Compound Name PMID29671355-Compound-21 Patented [35]
MOA Inhibitor
Activity IC50 = 2120 nM
External Link
 Compound Name PMID29671355-Compound-62 Patented [35]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
 Compound Name PMID29671355-Compound-43 Patented [35]
MOA Inhibitor
Activity IC50 = 23 nM
External Link
 Compound Name PMID29671355-Compound-25 Patented [35]
MOA Inhibitor
Activity IC50 = 175 nM
External Link
 Compound Name AN-9 Discontinued in Phase 2 [30]
Synonyms
Pivanex; Pivalyloxymethyl butyrate; AN 9; AN9; AN 9 (ion exchanger); Butanoyloxymethyl 2,2-dimethylpropanoate; Butanoicacid, (2,2-dimethyl-1-oxopropoxy)methyl ester; N-(5-amino-9,10-dioxoanthracen-1-yl)acetamide; N-(5-amino-9,10-dioxo-9,10-dihydroanthracen-1-yl)acetamide; ((2,2-Dimethylpropanoyl)oxy)methyl butanoate;1,5-BIS[3-(DIETHYLAMINO)PROPIONAMIDO]ANTHRACENE-9,10-DIONE
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Tacedinaline Discontinued in Phase 2 [31]
Synonyms
Acetyldinaline; Tacedinalina; Goe 5549; PD 123654; Ci-994; Goe-5549; PD-123654; Tacedinalina [INN-Spanish]; Tacedinaline [USAN:INN]; C.I. 994; Tacedinaline (USAN/INN); 4-(Acetylamino)-N-(2-aminophenyl)benzamide; 4-acetamido-N-(2-aminophenyl)benzamide; 4-acetamido-n-(2-aminophenyl)benzamid; 4-acetylamino-N-(2'-aminophenyl)benzamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 50 nM
External Link
 Compound Name Pyroxamide Discontinued in Phase 1 [31]
Synonyms
POLAR HYBRID COMPOUND; Suberoyl-3-aminopyridineamide hydroxamic acid; N-Hydroxy-N'-3-pyridinyloctanediamide; N'-hydroxy-N-pyridin-3-yloctanediamide; N-hydroxy-n'-(pyridin-3-yl)octanediamide; N-Hydroxy-N'-(3-pyridyl)-1,8-octanediamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 2.7 nM
External Link
 Compound Name M-carboxycinnamic acid bishydroxamide Preclinical [31]
Synonyms
Cbha; Histone Deacetylase Inhibitor II; HDInhib_000062; M-Carboxycinnamic Acid bis-Hydroxamide; N-hydroxy-3-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]benzamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 nM
External Link
 Compound Name HC-Toxin Preclinical [31]
Synonyms
HC Toxin; Cyclo(aoe-pro-ala-ala); Cyclo(2-amino-8-oxo-9,10-epoxydecanoic acid-prolyl-alanyl-alanine); Cyclic(L-alanyl-D-alanyl-eta-oxo-L-alpha-aminooxiraneoctanoyl-D-prolyl); Cyclo(L-alanyl-D-alanyl-(alphaS,2S)-alpha-amino-eta-oxooxiraneoctanoyl-D-prolyl); (3S,6R,9S,12R)-6,9-dimethyl-3-[6-(oxiran-2-yl)-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name SK-7068 Preclinical [31]
Synonyms
N-[[4-[(E)-2-(hydroxycarbamoyl)ethenyl]phenyl]methyl]-4-pyrrolidin-1-yl-benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Scriptaid Preclinical [31]
Synonyms
CGK1026; IN1099; SB-556629; GNF-PF-2024; N-Hydroxy-1,3-dioxo-1H-benz(de)isoquinoline-2(3H)-hexan amide; 6-(1,3-Dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-hexanoic acid hydroxyamide; 6-(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-N-hydroxyhexanamide; 6-(1,3-dioxobenzo[de]isoquinolin-2-yl)-N-hydroxyhexanamide
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1.5 nM
External Link
 Compound Name 4SC-202 Preclinical [29]
MOA Inhibitor
External Link
 Compound Name Chlamydocin Preclinical [31]
Synonyms
HDInhib_000038; Cyclic(2-methylalanyl-L-phenylalanyl-D-propyl-L-alpha-amino-eta-oxooxiraneoctanoyl); (3S,9S,12R)-3-benzyl-6,6-dimethyl-9-[6-[(2S)-oxiran-2-yl]-6-oxohexyl]-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone; (3s,9s,14ar)-9-benzyl-6,6-dimethyl-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}decahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetrone
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name SK-7041 Preclinical [31]
Synonyms
IN-2001; 4-(dimethylamino)-N-[[4-[(E)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Depudecin Preclinical [31]
Synonyms
(1R)-1-[(2S,3S)-3-[(E)-2-[(3S)-3-[(1R)-1-hydroxyethyl]oxiran-2-yl]ethenyl]oxiran-2-yl]prop-2-en-1-ol; 139508-73-9
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Oxamflatin Terminated [31]
Synonyms
NSC729360; CHEBI:258842; I14-11718; NCGC00165855-01; (2E)-5-(3-(phenylsulfonylamino)phenyl)pent-2-ene-4-ynohydroxamic acid; (2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic Acid; (E)-5-[3-(benzenesulfonamido)phenyl]-N-hydroxypent-2-en-4-ynamide; 151720-43-3
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide Investigative [38]
Synonyms
UNII-2OJV8MB11B; EX-2; 2OJV8MB11B; CHEMBL1083439; 851365-34-9; Benzamide, N-(((6-(hydroxyamino)-6-oxohexyl)amino)carbonyl)-; Benzamide, N-[[[6-(hydroxyamino)-6-oxohexyl]amino]carbonyl]-; SCHEMBL4258321; CTK2I4390; DTXSID80234280; VQLQZMGNGMOMPU-UHFFFAOYSA-N; BDBM50319235
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 16 nM
External Link
 Compound Name N,8-dihydroxy-8-(naphthalen-2-yl)octanamide Investigative [39]
Synonyms
CHEMBL319738; SCHEMBL3382032; JWCSCYWHCCHTEF-UHFFFAOYSA-N; BDBM50114820; N-Hydroxy-8-hydroxy-8-(2-naphthyl)octanamide; 8-Hydroxy-8-naphthalen-2-yl-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 35 nM
External Link
 Compound Name N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide Investigative [40]
Synonyms
CHEMBL216292; SCHEMBL5903988
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1130 nM
External Link
 Compound Name N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide Investigative [39]
Synonyms
CHEMBL98911; SCHEMBL3378753; BDBM50114831; 8-Oxo-8-pyridin-3-yl-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 153 nM
External Link
 Compound Name NSC-746457 Investigative [41]
MOA Inhibitor
Activity IC50 = 104 nM
External Link
 Compound Name 4-Benzenesulfonylamino-N-hydroxy-benzamide Investigative [42]
Synonyms
CHEMBL98345; SCHEMBL15480538; BDBM50105682; N-hydroxy-4-(phenylsulfonamido)benzamide; 4-(Phenylsulfonylamino)benzohydroximic acid
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 5000 nM
External Link
 Compound Name N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide Investigative [39]
Synonyms
CHEMBL320909; SCHEMBL1520961; AQLMJRZLPWGPGD-UHFFFAOYSA-N; BDBM50114827; N-Hydroxy-6-(2-naphthoyl)hexanamide; 7-Naphthalen-2-yl-7-oxo-heptanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 35 nM
External Link
 Compound Name 4-tert-butyl-N-hydroxybenzamide Investigative [43]
Synonyms
62034-73-5; CHEMBL249284; Benzamide, 4-(1,1-dimethylethyl)-N-hydroxy-; p-tert-butyl benzohydroxamic acid; Oprea1_740446; SCHEMBL5696343; 4-tert-Butylbenzhydroxamic Acid; 4-tert-Butylbenzohydroxamic acid; CTK2C8432; DTXSID80613051; BDBM50215019; 4-(tert-butyl )-benzhydroxamic acid; ZINC19478595; AKOS000181279
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 715 nM
External Link
 Compound Name N-hydroxy-7-(naphthalen-2-yloxy)heptanamide Investigative [44]
Synonyms
CHEMBL217083
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.9 nM
External Link
 Compound Name 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide Investigative [38]
Synonyms
CHEMBL1083441; SCHEMBL4928514; WUKFQTZVXXYEAB-UHFFFAOYSA-N
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8280 nM
External Link
 Compound Name N-hydroxy-8-(naphthalen-2-yl)non-8-enamide Investigative [39]
Synonyms
CHEMBL95535; SCHEMBL3382075; BDBM50114823; 8-Naphthalen-2-yl-non-8-enoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 8 nM
External Link
 Compound Name N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide Investigative [40]
Synonyms
CHEMBL216509; SCHEMBL5903774; BDBM50198477
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 243 nM
External Link
 Compound Name N-hydroxy-5-phenylthiophene-2-carboxamide Investigative [40]
Synonyms
CHEMBL217573; SCHEMBL5903684
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 900 nM
External Link
 Compound Name Azithromycin-N-benzyltriazolyldecahydroxamic Acid Investigative [45]
Synonyms
CHEMBL496761; SCHEMBL14328159; BDBM27184; triazole-linked azithromycin-based compound, 16h
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide Investigative [44]
Synonyms
CHEMBL265479
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18.8 nM
External Link
 Compound Name 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide Investigative [39]
Synonyms
CHEMBL95313; SCHEMBL1520838; BDBM50114816; 8-Biphenyl-4-yl-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5 nM
External Link
 Compound Name N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide Investigative [40]
Synonyms
CHEMBL217816; SCHEMBL5903934
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1260 nM
External Link
 Compound Name Gymnochrome E Investigative [46]
MOA Inhibitor
Activity IC50 = 10900 nM
External Link
 Compound Name N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide Investigative [39]
Synonyms
CHEMBL451182; SCHEMBL3382916; SCHEMBL3382922; PGGPUSMJSOKMEA-XBXARRHUSA-N; ZINC13474418; BDBM50114829; (E)-N-Hydroxy-8-(2-naphthyl)-7-octenamide; 8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide; (E)-8-Naphthalen-2-yl-oct-7-enoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6 nM
External Link
 Compound Name N-hydroxybenzo[b]thiophene-2-carboxamide Investigative [47]
Synonyms
CHEMBL245946; 211172-97-3; Benzo[b]thiophene-2-carboxamide, N-hydroxy-; SCHEMBL999904; CTK0J7987; DTXSID40470925; BDBM50216024; benzothiophene-2-carbohydroxamic acid
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 670 nM
External Link
 Compound Name 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide Investigative [44]
Synonyms
CHEMBL426516
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.6 nM
External Link
 Compound Name 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide Investigative [39]
Synonyms
CHEMBL319070; SCHEMBL3382402; RFYYZRFJBNAHCG-UHFFFAOYSA-N; BDBM50114817; n-hydroxy-7-(4-bromobenzoyl)heptanamide; 8-(4-Bromo-phenyl)-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 45 nM
External Link
 Compound Name N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide Investigative [39]
Synonyms
CHEMBL95990; SCHEMBL1521117; NIGGAQZXTHMKPL-UHFFFAOYSA-N; BDBM50114822; N-Hydroxy-6-(4-methoxybenzoyl)hexanamide; 7-(4-Methoxy-phenyl)-7-oxo-heptanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 450 nM
External Link
 Compound Name N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide Investigative [39]
Synonyms
CHEMBL95885; SCHEMBL3382183; BDBM50114815; 8-(2-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 95 nM
External Link
 Compound Name N-hydroxy-6-oxo-6-phenylhexanamide Investigative [39]
Synonyms
CHEMBL95152; SCHEMBL1521154; BDBM50114819; 6-Oxo-6-phenyl-hexanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1500 nM
External Link
 Compound Name N-hydroxy-8-(naphthalen-2-yl)octanamide Investigative [39]
Synonyms
CHEMBL95747; SCHEMBL3378763; KWFDCRKEDDNSLQ-UHFFFAOYSA-N; N-Hydroxy-8-(2-naphthyl)octanamide; BDBM50114833; ZINC13474419; 8-Naphthalen-2-yl-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 25 nM
External Link
 Compound Name ADS-102550 Investigative [40]
Synonyms
CHEMBL217716; SCHEMBL5903759; BDBM50198218
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 29 nM
External Link
 Compound Name N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide Investigative [39]
Synonyms
CHEMBL95835; SCHEMBL3383312; LIOTZVIDBXLBAC-UHFFFAOYSA-N; n-hydroxy-7-(p-anisoyl)heptanamide; BDBM50114826; 8-(4-Methoxy-phenyl)-8-oxo-octanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 15 nM
External Link
 Compound Name N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide Investigative [48]
Synonyms
CHEMBL238569; SCHEMBL1064835
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1000 nM
External Link
 Compound Name N-hydroxy-2,2'-bithiophene-5-carboxamide Investigative [40]
Synonyms
CHEMBL217750; SCHEMBL5903723; BDBM50198479
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2500 nM
External Link
 Compound Name ADS-100380 Investigative [40]
Synonyms
CHEMBL216885; SCHEMBL5904027; BDBM50198221
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 750 nM
External Link
 Compound Name N-hydroxy-7-oxo-7-phenylheptanamide Investigative [39]
Synonyms
CHEMBL95916; SCHEMBL1521257; BDBM50114832; 7-Oxo-7-phenyl-heptanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 500 nM
External Link
 Compound Name 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide Investigative [38]
Synonyms
CHEMBL1083440; SCHEMBL4922807
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 145 nM
External Link
 Compound Name SK-683 Investigative [49]
Synonyms
CHEMBL116620; SCHEMBL8089576; BDBM50148757
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 nM
External Link
 Compound Name N-hydroxy-9-oxo-9-phenylnonanamide Investigative [39]
Synonyms
CHEMBL99810; SCHEMBL1521077; BDBM50114824; 9-Oxo-9-phenyl-nonanoic acid hydroxyamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 135 nM
External Link
 Compound Name N-Hydroxy-N'-(4-methylphenyl)octanediamide Investigative [50]
Synonyms
CHEMBL1092762; BDBM50314138
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 76 nM
External Link
 Compound Name N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093043; BDBM50314143
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(2-aminophenyl)quinoxaline-6-carboxamide Investigative [51]
Synonyms
benzamide-type inhibitor, 20; CHEMBL236060; BDBM19424
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
 Compound Name 7-Biphenyl-4-yl-heptanoic acid hydroxyamide Investigative [52]
Synonyms
CHEMBL125098; BDBM50222335; 7-(4-Biphenylyl)heptanehydroximic acid
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(2-Ethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093040; BDBM50314142
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid Investigative [53]
Synonyms
CHEMBL115049; 436150-72-0; SCHEMBL7368556; CTK1D2674; DTXSID40658342; BDBM50221807; 8-[([1,1'-Biphenyl]-4-yl)oxy]-2-oxooctanoic acid; Octanoic acid, 8-([1,1'-biphenyl]-4-yloxy)-2-oxo-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 1,1,1-Trifluoro-8-phenoxy-octan-2-one Investigative [54]
Synonyms
CHEMBL114796; BDBM50217940
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide Investigative [53]
Synonyms
CHEMBL114184; SCHEMBL3383144
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1092032; BDBM50314141
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-Phenoxy-heptanoic acid hydroxyamide Investigative [52]
Synonyms
CHEMBL124322; N-hydroxy-7-phenoxyheptanamide; 7-Phenoxyheptanehydroximic acid
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one Investigative [54]
Synonyms
CHEMBL117916; SCHEMBL7366611; BDBM50217945
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide Investigative [55]
Synonyms
CHEMBL1290142; A1-02262; SCHEMBL1004139; SOMDVJCUFVPZKM-UHFFFAOYSA-N; BDBM50331109; 9H-Carbazole-9-hexanamide, N-hydroxy-; 6-Carbazol-9-ylhexanoic acid hydroxyamide; US8748451, 1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3074 nM
External Link
 Compound Name Desclasinose Azithromycinarylalkyl Hydroxamate Investigative [45]
Synonyms
CHEMBL454025; SCHEMBL14329692; BDBM27176; Desclasinose Azithromycinarylalkyl Hydroxamate, 10
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(4-Ethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093042; BDBM50314139
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093713; BDBM50314133
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide Investigative [56]
Synonyms
CHEMBL473270
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 9 nM
External Link
 Compound Name N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093357; BDBM50314144
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Azithromycin-N-benzyltriazolyloctahydroxamic Acid Investigative [45]
Synonyms
SCHEMBL8976909; CHEMBL455342; BDBM27181; triazole-linked azithromycin-based compound, 16e
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(4-hydroxybiphenyl-3-yl)benzamide Investigative [57]
Synonyms
CHEMBL269935; SCHEMBL5724398; BDBM50232005
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 58 nM
External Link
 Compound Name AZUMAMIDE E Investigative [58]
Synonyms
CHEMBL402363
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 50 nM
External Link
 Compound Name Azithromycin-N-benzyltriazolylnonahydroxamic Acid Investigative [45]
Synonyms
CHEMBL509089; SCHEMBL14329756; BDBM27183; triazole-linked azithromycin-based compound, 16g
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-N'-(3-methylphenyl)octanediamide Investigative [50]
Synonyms
CHEMBL1089339; BDBM50314136
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 57 nM
External Link
 Compound Name 8-Phenyl-octanoic acid hydroxyamide Investigative [52]
Synonyms
CHEMBL123624; N-Hydroxy-8-phenyloctanamide; SCHEMBL5807174
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Azithromycin-N-benzyltriazolylhexahydroxamic Acid Investigative [45]
Synonyms
CHEMBL446811; SCHEMBL14328156; CHEMBL3735805; BDBM27177; triazole-linked azithromycin-based compound, 16a
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(3-Ethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093041; BDBM50314134
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093359; BDBM50314135
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-N'-(4-methoxyphenyl)octanediamide Investigative [50]
Synonyms
CHEMBL1091487; BDBM50314137
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 71 nM
External Link
 Compound Name AZUMAMIDE B Investigative [58]
Synonyms
CHEMBL402727
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1830 nM
External Link
 Compound Name 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [54]
Synonyms
CHEMBL116023; SCHEMBL7368359; BDBM50218558
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Azithromycinarylalkylhydroxamic Acid Investigative [45]
Synonyms
CHEMBL510806; SCHEMBL14329660; BDBM27175; Azithromycinarylalkylhydroxamic Acid, 8
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-N'-(2-methylphenyl)octanediamide Investigative [50]
Synonyms
CHEMBL1076794; BDBM50314140
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 576 nM
External Link
 Compound Name nexturastat A Investigative [59]
Synonyms
S7473
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 360 nM
External Link
 Compound Name AZUMAMIDE C Investigative [58]
Synonyms
CHEMBL257972
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 20 nM
External Link
 Compound Name N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide Investigative [50]
Synonyms
CHEMBL1093358; BDBM50314145
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide Investigative [60]
Synonyms
CHEMBL511212; BDBM50258645
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
 Compound Name LARGAZOLE Investigative [61]
Synonyms
CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10.09 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Investigative [62]
Synonyms
CHEMBL393260
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 36 nM
External Link
 Compound Name 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Investigative [63]
Synonyms
CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 48 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Investigative [62]
Synonyms
CHEMBL390991
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.7 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Investigative [62]
Synonyms
CHEMBL394261
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Investigative [62]
Synonyms
CHEMBL391384
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5.3 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Investigative [62]
Synonyms
CHEMBL393261
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 170 nM
External Link
 Compound Name N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Investigative [60]
Synonyms
CHEMBL512644; SCHEMBL8226957
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 33 nM
External Link
 Compound Name N-(2-aminophenyl)nicotinamide Investigative [57]
Synonyms
N-(2-Amino-phenyl)-nicotinamide; 436089-31-5; N-(2-aminophenyl)pyridine-3-carboxamide; CHEMBL236678; AC1LMN6K; SCHEMBL18086514; CTK4I7538; DTXSID50360661; CHEBI:125506; ZINC873967; BDBM50220259; 3463AE; AKOS000129725; RTR-042156; MCULE-7933541910; N-(2-aminophenyl)-3-pyridylcarboxamide; ZB014940; ACM436089315; ST086607; ASN 01337807; KB-298440; TR-042156; BC4148434; SR-01000329900; SR-01000329900-1; BRD-K20880473-001-04-6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2600 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Investigative [62]
Synonyms
CHEMBL241555
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.2 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Investigative [62]
Synonyms
CHEMBL428737
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 88 nM
External Link
 Compound Name N-(4-aminobiphenyl-3-yl)nicotinamide Investigative [57]
Synonyms
CHEMBL255805; BDBM50232035
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 48 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Investigative [62]
Synonyms
CHEMBL238587
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4.7 nM
External Link
 Compound Name N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Investigative [57]
Synonyms
CHEMBL256440; SCHEMBL1066609
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 65 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Investigative [62]
Synonyms
CHEMBL238596; BDBM50222727
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 94 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Investigative [62]
Synonyms
CHEMBL393961
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6.4 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Investigative [62]
Synonyms
CHEMBL391383
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6.2 nM
External Link
 Compound Name N-(2-aminophenyl)-4-methoxybenzamide Investigative [51]
Synonyms
AC1LFX2W; Cambridge id 5129152; Oprea1_722128; benzamide-type inhibitor, 22; CHEMBL236061; SCHEMBL5226034; BDBM19426; CTK7A1998; MolPort-001-019-504; BDYVCYUXCNZYRW-UHFFFAOYSA-N; ZINC281656; STK156256; AKOS000130378; MCULE-9183453747; N-(2-Amino-phenyl)4-methoxy-benzamide; N-(2-amino-phenyl)-4-methoxy-benzamide; NCGC00240897-01; N1-(4-methoxybenzoyl)-1,2-benzenediamine; N1-(4-methoxy-benzoyl)-1,2-benzenediamine; ST50908739; N-(2-aminophenyl)(4-methoxyphenyl)carboxamide; SR-01000196394
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2000 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Investigative [62]
Synonyms
CHEMBL393464
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.7 nM
External Link
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Investigative [62]
Synonyms
CHEMBL238829; BDBM50222732
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.9 nM
External Link
 Compound Name 4-Phenylbutyrohydroxamic acid Investigative [64]
Synonyms
N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 295 nM
External Link
 Compound Name 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative [65]
Synonyms
CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 65 nM
External Link
 Compound Name ST-3050 Investigative [66]
Synonyms
CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3060 nM
External Link
 Compound Name Octanedioic acid bis-hydroxyamide Investigative [67]
Synonyms
Suberohydroxamic acid
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 19 nM
External Link
 Compound Name ST-2986 Investigative [66]
Synonyms
CHEMBL471041; SCHEMBL3444455; BDBM50278219
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5480 nM
External Link
 Compound Name 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative [54]
Synonyms
9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 7800 nM
External Link
 Compound Name 7-Mercapto-heptanoic acid phenylamide Investigative [68]
Synonyms
Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 218 nM
External Link
 Compound Name 6-benzenesulfinylhexanoic acid hydroxamide Investigative [69]
Synonyms
6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative [70]
Synonyms
CHEMBL193959
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative [68]
Synonyms
CHEMBL112311
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-phenylacetylamino-benzamide Investigative [71]
Synonyms
CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative [68]
Synonyms
CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative [72]
Synonyms
CHEMBL143674; SCHEMBL673760
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [73]
Synonyms
CHEMBL126355; BDBM50222394
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative [74]
Synonyms
SCHEMBL8082656; CHEMBL165162; ZINC13472304
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(6-Mercapto-hexyl)-benzamide Investigative [68]
Synonyms
CHEMBL112364; BDBM50223650
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [74]
Synonyms
CHEMBL167455
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative [71]
Synonyms
SCHEMBL675474
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-benzenesulfonylhexanoic acid hydroxamide Investigative [69]
Synonyms
CHEMBL203207
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative [54]
Synonyms
SCHEMBL7373122; CHEMBL116578
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative [68]
Synonyms
CHEMBL111806; SCHEMBL14812153
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 4-Butyrylamino-N-hydroxy-benzamide Investigative [72]
Synonyms
CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [73]
Synonyms
CHEMBL127328
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative [68]
Synonyms
CHEMBL320323
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative [75]
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative [71]
Synonyms
SCHEMBL676079
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative [68]
Synonyms
CHEMBL324126
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative [68]
Synonyms
CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-Phenoxy-hexane-1-thiol Investigative [68]
Synonyms
CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 4-Benzoylamino-N-hydroxy-benzamide Investigative [71]
Synonyms
SCHEMBL673678; CHEMBL191227
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [65]
Synonyms
CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [54]
Synonyms
CHEMBL112148; SCHEMBL7364383; BDBM50218532
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [73]
Synonyms
CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-Mercapto-hexanoic acid phenylamide Investigative [68]
Synonyms
CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 791 nM
External Link
 Compound Name Cyclostellettamine derivative Investigative [76]
Synonyms
CHEMBL88332
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative [65]
Synonyms
CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 5-Mercapto-pentanoic acid phenylamide Investigative [68]
Synonyms
N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative [74]
Synonyms
SCHEMBL8090513; CHEMBL164872; ZINC13472303
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative [70]
Synonyms
CHEMBL193979
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative [75]
Synonyms
CHEMBL271677; SCHEMBL4156413
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative [73]
Synonyms
CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative [71]
Synonyms
SCHEMBL676080
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative [77]
Synonyms
N-hydroxy-4-(3-phenylpropanamido)benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative [71]
Synonyms
SCHEMBL7311087
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 8-Oxo-8-phenyl-octanoic acid Investigative [74]
Synonyms
8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative [71]
Synonyms
CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 6-phenylsulfanylhexanoic acid hydroxamide Investigative [69]
Synonyms
Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name ST-2987 Investigative [66]
Synonyms
CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 790 nM
External Link
 Compound Name 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative [68]
Synonyms
CHEMBL112234
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative [78]
Synonyms
CHEMBL84288
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 8-Mercapto-octanoic acid phenylamide Investigative [68]
Synonyms
8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 294 nM
External Link
 Compound Name N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative [74]
Synonyms
CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative [54]
Synonyms
CHEMBL326529; SCHEMBL7365237; BDBM50217957
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative [68]
Synonyms
CHEMBL178779
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative [72]
Synonyms
CHEMBL143102
    Click to Show/Hide
MOA Inhibitor
External Link
 Compound Name PSAMMAPLIN A Investigative [65]
Synonyms
110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-
    Click to Show/Hide
MOA Inhibitor
External Link
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [79]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
 Compound Name Aflibercept Approved [80]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
 Compound Name Regorafenib Approved [81]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
 Compound Name Bevacizumab Approved [9]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
 Compound Name SYM-004 Phase 3 [9]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
 Compound Name Bevacizumab + Erlotinib Phase 3 [82]
External Link
 Compound Name CPI-613 Phase 3 [9]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
 Compound Name Bevacizumab Approved [80]
External Link
 Compound Name AlloStim Phase 2/3 [83]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
 Compound Name Sibrotuzumab Phase 2 [84]
External Link
 Compound Name CV301 Phase 2 [85]
External Link
 Compound Name Efatutazone Phase 2 [86]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
 Compound Name LOR-2040 Phase 2 [87]
External Link
 Compound Name RG7221 Phase 2 [88]
External Link
 Compound Name PEG-SN38 Phase 2 [89]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
 Compound Name MEGF0444A Phase 2 [90]
External Link
 Compound Name Encapsulated cell therapy Phase 1/2 [91]
External Link
 Compound Name AB928 Phase 1/2 [92]
External Link
 Compound Name MGD007 Phase 1 [88]
External Link
 Compound Name BNC-101 Phase 1 [93]
External Link
 Compound Name Navicixizumab Phase 1 [9]
External Link
 Compound Name RG7160 Discontinued in Phase 2 [94]
External Link
 Compound Name Nimesulide Terminated [95]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
 Compound Name Saracatinib Phase 2 [96]
External Link
 Compound Name G3139 + Irinotecan Investigative [97]
External Link
References
Ref 1 Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer. Adv Sci (Weinh). 2025 Mar;12(12):e2408845. doi: 10.1002/advs.202408845. Epub 2025 Jan 31.
Ref 2 LncRNA CARMN m6A demethylation by ALKBH5 inhibits mutant p53-driven tumour progression through miR-5683/FGF2. Clin Transl Med. 2024 Jul;14(7):e1777. doi: 10.1002/ctm2.1777.
Ref 3 A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61.
Ref 4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 5 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 6 Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. doi: 10.1038/cgt.2013.9. Epub 2013 Mar 8.
Ref 7 APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4(10):e881. doi: 10.1038/cddis.2013.417.
Ref 8 Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. doi: 10.1038/sj.cgt.7700562.
Ref 9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 10 INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. doi: 10.1517/14712598.2010.484801.
Ref 11 Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. doi: 10.1158/1078-0432.CCR-11-1817. Epub 2011 Oct 12.
Ref 12 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
Ref 13 SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. doi: 10.1158/0008-5472.CAN-14-0799. Epub 2014 Aug 21.
Ref 14 Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. doi: 10.1007/s00262-003-0493-5. Epub 2004 Feb 25.
Ref 15 Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. doi: 10.1016/j.ccr.2004.11.012.
Ref 16 National Cancer Institute Drug Dictionary (drug id 761551).
Ref 17 Prevent Oral Cancer With Mouthwash. Introgen Therapeutics.
Ref 18 An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77. doi: 10.1158/1535-7163.MCT-04-0341.
Ref 19 Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86.
Ref 20 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. doi: 10.1093/nar/28.1.235.
Ref 21 Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem. 2009 Nov 26;52(22):7044-53. doi: 10.1021/jm900681h.
Ref 22 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. doi: 10.1021/jm0601194.
Ref 23 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 24 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
Ref 25 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. doi: 10.1038/nrd3101.
Ref 26 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
Ref 27 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 28 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. doi: 10.1517/14728210903066809.
Ref 29 2011 Pipeline of 4SC AG.
Ref 30 Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
Ref 31 Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
Ref 32 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
Ref 33 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.
Ref 34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2658).
Ref 35 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 36 Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
Ref 37 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015;25(9):953-70. doi: 10.1517/13543776.2015.1045414. Epub 2015 Jul 13.
Ref 38 Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21.
Ref 39 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76.
Ref 40 Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9.
Ref 41 Histone deacetylase inhibitors through click chemistry. J Med Chem. 2008 Dec 11;51(23):7417-27.
Ref 42 Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett. 2001 Nov 5;11(21):2847-50.
Ref 43 Design of novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4619-24.
Ref 44 Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41.
Ref 45 Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68.
Ref 46 Gymnochromes E and F, cytotoxic phenanthroperylenequinones from a deep-water crinoid, Holopus rangii. J Nat Prod. 2010 Apr 23;73(4):712-5.
Ref 47 Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29.
Ref 48 N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6729-33.
Ref 49 On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem. 2004 Jun 17;47(13):3409-17.
Ref 50 Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50.
Ref 51 Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. doi: 10.1021/jm701079h. Epub 2007 Oct 17.
Ref 52 A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. doi: 10.1016/j.bmcl.2003.07.012.
Ref 53 Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. doi: 10.1016/s0960-894x(03)00685-1.
Ref 54 Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. doi: 10.1016/s0960-894x(02)00754-0.
Ref 55 Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70.
Ref 56 Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40.
Ref 57 SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. doi: 10.1016/j.bmcl.2008.10.052. Epub 2008 Oct 14.
Ref 58 Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
Ref 59 Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9.
Ref 60 Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6.
Ref 61 Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67.
Ref 62 Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
Ref 63 Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
Ref 64 Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. doi: 10.1038/nchembio.313. Epub 2010 Feb 7.
Ref 65 Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. doi: 10.1021/jm0303094.
Ref 66 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. doi: 10.1016/j.bmcl.2009.02.029. Epub 2009 Feb 12.
Ref 67 Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem. 2002 Jul 18;45(15):3296-309. doi: 10.1021/jm0208119.
Ref 68 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-32. doi: 10.1021/jm049207j.
Ref 69 Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. doi: 10.1021/jm051010j.
Ref 70 Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. doi: 10.1016/j.bmcl.2005.02.075.
Ref 71 Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749.
Ref 72 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. doi: 10.1021/jm0303655.
Ref 73 Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. doi: 10.1016/j.bmcl.2003.09.007.
Ref 74 Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. doi: 10.1021/jm015568c.
Ref 75 New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. doi: 10.1016/j.bmcl.2008.02.007. Epub 2008 Feb 8.
Ref 76 Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. doi: 10.1016/j.bmcl.2004.02.062.
Ref 77 Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur J Med Chem. 2009 Nov;44(11):4470-6. doi: 10.1016/j.ejmech.2009.06.010. Epub 2009 Jun 17.
Ref 78 Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. doi: 10.1016/j.bmcl.2004.03.012.
Ref 79 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 80 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 81 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 82 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 83 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 84 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 85 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 86 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 87 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 88 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 89 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 90 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 91 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 92 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 93 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 94 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 95 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 96 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 97 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.